EGFR is often overexpressed in many tumors, including lung cancer, breast cancer, colorectal cancer, and pancreatic tumors.[[qv: 12]] Notably, EGFR inhibitor has been approved for the clinical treatment of lung and pancreatic cancer. This evidence concerns the gene EGFR and breast carcinoma.